Key points are not available for this paper at this time.
The fast sample readout speed, high reproducibility, wide compound coverage, minimum carryover, and the tolerance to complex sample matrices of AEMS have demonstrated its advantages over other technologies in this field, with broad applicability to a diverse range of drug discovery workflows. However, the current platform still has challenges for some assays due to having less sensitivity compared with liquid chromatography-mass spectrometry (LC-MS), and the lack of chromatographic separation for isomeric interferences. Despite the remaining hurdles, AEMS is becoming an attractive high-throughput analytical platform in drug discovery. Additional system developments would enable its further adoption in the future.
Chang Liu (Sat,) studied this question.